Loading...
 

Volume 32, Issue 1, March 2021




Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2021;32(1):74-80
Gout and AA-Amyloidosis: A Case-Based Review
Authors Information

1. Pirogov Russian National Research Medical University (RNRMU), Moscow, Russian Federation

2. I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

Margarita Gromova 

Abstract
Background: AA-amyloidosis complicates many chronic infections and inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, but its relationship to gout is extremely rare. As it is unknown definitely what the pathophysiological connections between gout and amyloidosis are, treatment issues of the diseases are open for discussion. Aim: To establish a link between gout and AA-amyloidosis, and to improve the quality of treatment in patients suffering from gout and AA-amyloidosis. Methods: We reviewed the English-language literature sources, searching not only for rare cases of the combination of gout and AA amyloidosis, but also detailed descriptions of the medical treatments for the two pathologies. Results: By July 2020, we had identified 14 cases describing AA amyloidosis in patients with gout. Most of those patients had been suffering tophaceous gout for at least 10 years, and were prescribed various methods of treatment; however, not all patients took colchicine regularly. In some cases, therapy with allopurinol and colchicine was effective against attacks of gouty arthritis, although amyloidogenic inflammation was not controlled sufficiently. However, there were no cases that described in detail the successful treatment of both diseases. Besides those 14 patients described in literature, we examined one more patient with amyloidosis that is secondary to gout, in whom the protein of amyloid A (AA) had affected the kidneys, intestines, and adrenal glands. The patient has been successfully treated with the combination of canakinumab, prednisone, colchicine and allopurinol. Conclusion: Clinicians should be aware that patients may have atypical combinations of diseases like gout and amyloidosis. The obtained results help to explain some pathogenic processes associated with AA-amyloidosis. Further research is necessary to confirm the effectiveness of different treatment options such as lifestyle biologic agents or other medicines with anti-inflammatory properties. 

Article Submitted: 24 Jun 2020; Revised Form: 7 Jul 2020; Article Accepted: 20 Jul 2020; Available Online: Feb 5, 2021

https://doi.org/10.31138/mjr.32.1.74

This work is licensed under a Creative Commons Attribution 4.0 International License (CC-BY). 

©Gromova MA, Tsurko VV.